- Investors & Media
- Investors & Media
- Contact Us
Financial highlights of the 2015 third quarter included: Total revenues of $16.1 million compared with $17.2 million for the third quarter of 2014; Proprietary product revenue of $9.6 million compared with $9.1 million in the 2014 third quarter; Distributed product revenue of $6.5 million compared with $8.0 million in the same period of 2014; Gross profit of $3.7 million compared with $4.4 million in the year-ago third quarter; and Net loss of $4.6 million compared with a net loss of $2.9 million in the year-ago third quarter.
Kamada management will host an investment community conference call on Tuesday, November 10, 2015 at 8:30 a.m. Eastern time to discuss these results and answer questions.
NESS ZIONA, Israel (September 8, 2015) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will participate at the…
Pharmaceutical executive brings over 40 years of clinical, academic and industry leadership
Financial highlights of the 2015 second quarter included:
Total revenues of $19.2 million compared with $15.8 million for the second quarter of 2014; Gross profit of $3.6 million compared with a gross loss of $0.10 million in the year-ago second quarter; Adjusted net loss of $1.8 million compared with an adjusted net loss of $7.4 in the year-ago second quarter.
Kamada management will host an investment community conference call on Thursday, July 30, 2015 at 8:30 a.m. Eastern time to discuss these results and answer questions.
The Company expects to report complete financial results for the three and six months ended June 30, 2015 on July 30th. Information regarding the conference call with investors will be provided in a separate notification in the coming weeks.
Demonstrated profound safety of multiple intravenous doses of AAT therapy for treatment of newly diagnosed type 1 diabetes while maintaining glycemic control and less of a decrease in C-Peptide levelsץ
Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016.
Additional analyses demonstrate that inhaled AAT is able to change the nature of exacerbations to events with fewer symptoms (statistically significant), a change that correlates with the benefit seen in lung function.
Data highlighted in panel discussion with renowned pulmonology experts who specialize in treating patients with alpha-1 antitrypsin deficiency will serve as basis for MAA submission in Europe